Patients with diabetes receiving treatment for CRC may experience more neuropathic symptoms
the ONA take:
Patients with colorectal cancer who also have diabetes experienced more neuropathic symptoms, regardless of cancer treatment, according to a recent study published in the Journal of Cancer Survivorship.
Researchers found that patients with colorectal cancer and diabetes experienced more mild to severe neuropathic symptoms, including tingling fingers or hands, tingling toes or feet, numbness in toes or feet, and erectile dysfunction among men, than patients without diabetes.
The study demonstrated no differences in cancer treatment between patients with colorectal cancer and diabetes compared with those without diabetes.
The authors conclude that diabetes rather than chemotherapy results in more neuropathic symptoms among patients with cancer and diabetes compared with those without diabetes.
The findings ultimately suggest that up to 39% of cancer survivors might expect mostly mild, neuropathic symptoms, with more symptoms occurring in patients with diabetes.
Neuropathic symptoms are typically associated with the chemotherapy agent oxaliplatin, which is often used in combination with fluorouracil, leucovorin, and sometimes irinotecan in the treatment of colorectal cancer.
Patients with colorectal cancer who also have diabetes experienced more neuropathic symptoms, regardless of cancer treatment.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|